ES3068042T3 - Ligandos para inhibir la formación de proteínas multiméricas - Google Patents

Ligandos para inhibir la formación de proteínas multiméricas

Info

Publication number
ES3068042T3
ES3068042T3 ES19779920T ES19779920T ES3068042T3 ES 3068042 T3 ES3068042 T3 ES 3068042T3 ES 19779920 T ES19779920 T ES 19779920T ES 19779920 T ES19779920 T ES 19779920T ES 3068042 T3 ES3068042 T3 ES 3068042T3
Authority
ES
Spain
Prior art keywords
protein
tnf
variant
polypeptide
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19779920T
Other languages
English (en)
Spanish (es)
Inventor
Olivier Kitten
Mathieu Cinier
Simon Huet
Anne Chevrel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affilogic SAS
Original Assignee
Affilogic SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affilogic SAS filed Critical Affilogic SAS
Application granted granted Critical
Publication of ES3068042T3 publication Critical patent/ES3068042T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES19779920T 2018-10-07 2019-10-06 Ligandos para inhibir la formación de proteínas multiméricas Active ES3068042T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306324.7A EP3632924A1 (en) 2018-10-07 2018-10-07 Binders for inhibiting formation of multimeric proteins
PCT/EP2019/076986 WO2020074402A1 (en) 2018-10-07 2019-10-06 Binders for inhibiting formation of multimeric proteins

Publications (1)

Publication Number Publication Date
ES3068042T3 true ES3068042T3 (es) 2026-05-27

Family

ID=64017330

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19779920T Active ES3068042T3 (es) 2018-10-07 2019-10-06 Ligandos para inhibir la formación de proteínas multiméricas

Country Status (5)

Country Link
US (1) US20210380647A1 (cg-RX-API-DMAC7.html)
EP (2) EP3632924A1 (cg-RX-API-DMAC7.html)
JP (2) JP7699539B2 (cg-RX-API-DMAC7.html)
ES (1) ES3068042T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020074402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
EP4043481A1 (en) 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
EP4190358A1 (en) 2021-12-05 2023-06-07 Affilogic Polypeptide as carrier for intestinal barrier crossing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011891A2 (en) * 2005-07-15 2007-01-25 Strategene California Dna binding protein-polymerase chimeras
ZA200810836B (en) 2006-05-26 2010-07-28 Obodies Ltd OB fold domains
EP1930342B1 (en) * 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
FR2974816A1 (fr) 2011-05-04 2012-11-09 Centre Nat Rech Scient Methode de generation de proteines
FR3004650B1 (fr) 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
WO2017161096A1 (en) * 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules

Also Published As

Publication number Publication date
JP2022501063A (ja) 2022-01-06
JP7699539B2 (ja) 2025-06-27
JP2025108528A (ja) 2025-07-23
EP3861011B1 (en) 2026-02-11
WO2020074402A1 (en) 2020-04-16
EP3861011A1 (en) 2021-08-11
EP3861011C0 (en) 2026-02-11
US20210380647A1 (en) 2021-12-09
EP3632924A1 (en) 2020-04-08